Abstract

Outcomes for patients with relapsed extensive-stage small cell lung cancer (ES-SCLC) remain poor with few therapeutic options after progression on first-line chemoimmunotherapy. Recently, lurbinectedin, a novel transcription inhibitor and alkylating agent, demonstrated a favorable response rate, duration of response, and toxicity profile, leading to its accelerated FDA approval of its use in this population. ES-SCLC is distinguished by a propensity for rapid progression, such that palliative radiotherapy (RT) is often delivered with the intent of alleviating symptoms while minimizing interruptions of systemic therapy.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.